640 related articles for article (PubMed ID: 28760314)
1. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2.
Coropciuc RG; Grisar K; Aerden T; Schol M; Schoenaers J; Politis C
Br J Oral Maxillofac Surg; 2017 Oct; 55(8):787-792. PubMed ID: 28760314
[TBL] [Abstract][Full Text] [Related]
2. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study.
Ristow O; Rückschloß T; Müller M; Berger M; Kargus S; Pautke C; Engel M; Hoffmann J; Freudlsperger C
J Craniomaxillofac Surg; 2019 Mar; 47(3):491-499. PubMed ID: 30642734
[TBL] [Abstract][Full Text] [Related]
3. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
4. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
5. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
[TBL] [Abstract][Full Text] [Related]
6. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
7. Management of Medication-Related Osteonecrosis of the Jaw.
Williams WB; O'Ryan F
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.
Aljohani S; Gaudin R; Weiser J; Tröltzsch M; Ehrenfeld M; Kaeppler G; Smeets R; Otto S
J Craniomaxillofac Surg; 2018 Sep; 46(9):1515-1525. PubMed ID: 29983309
[TBL] [Abstract][Full Text] [Related]
9. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
Nisi M; Karapetsa D; Gennai S; Ramaglia L; Graziani F; Gabriele M
J Craniomaxillofac Surg; 2018 Jul; 46(7):1153-1158. PubMed ID: 29802059
[TBL] [Abstract][Full Text] [Related]
10. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report.
Diniz-Freitas M; Fernández-Feijoo J; Diz Dios P; Pousa X; Limeres J
J Clin Periodontol; 2018 May; 45(5):570-577. PubMed ID: 29479739
[TBL] [Abstract][Full Text] [Related]
11. Successful conservative treatment of jaw osteonecrosis caused by denosumab in patients with multiple bone metastasis.
Ohga N; Sato J; Asaka T; Morimoto M; Yamazaki Y; Kitagawa Y
J Oral Sci; 2018; 60(1):159-162. PubMed ID: 29576576
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
13. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
14. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Oral Dis; 2018 Mar; 24(1-2):238-242. PubMed ID: 29480596
[TBL] [Abstract][Full Text] [Related]
15. Conservative non-surgical management in medication related osteonecrosis of the jaw: A retrospective study.
Albanese M; Zotti F; Capocasale G; Bonetti S; Lonardi F; Nocini PF
Clin Exp Dent Res; 2020 Oct; 6(5):512-518. PubMed ID: 32614524
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws.
Klingelhöffer C; Zeman F; Meier J; Reichert TE; Ettl T
J Craniomaxillofac Surg; 2016 Oct; 44(10):1694-1699. PubMed ID: 27591091
[TBL] [Abstract][Full Text] [Related]
18. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.
Matsumoto A; Sasaki M; Schmelzeisen R; Oyama Y; Mori Y; Voss PJ
Clin Oral Investig; 2017 Jan; 21(1):127-134. PubMed ID: 26924135
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
Halpern LR; Adams DR
Dent Clin North Am; 2024 Jan; 68(1):67-85. PubMed ID: 37951638
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
